Abstract
Frontal dementia gives rise to characteristic behavioral changes, which include altered emotions, profound alterations in personality and social conduct, and behavioral alterations constitute core and supportive symptoms laid out in the diagnostic criteria. There are some behavioral symptoms which are considered specific for frontal dementia, being present in at least 50% of cases. These includes loss of basic emotions and social embarrassment, selfishness, disinhibition, irritability, neglect, apathy, altered preference for sweet foods, with a tendency to continue eating for as long as food is present, or to steal food from others plates, motor and verbal stereotypies, wandering, and an absence of insightfulness. Albeit anatomical pathways are well known, there is no known therapy to prevent the advance of frontal dementia. The circuits involve a number of transmitters, receptor subtypes, and second messengers that can be potentially mediated pharmacologically. Though, rational treatments are currently limited . We present the possible actual and future therapeutic choices on the basis of anatomical and biochemical substrates.
Keywords: frontal dementia, serotonine, acetylcholine, dopamine
Letters in Drug Design & Discovery
Title: Difficulties in the Management of Frontal Dementia: Therapeutics Strategies
Volume: 2 Issue: 3
Author(s): Rita Moretti, Paola Torre, Rodolfo M. Antonello, Tatiana Cattaruzza and Giuseppe Cazzato
Affiliation:
Keywords: frontal dementia, serotonine, acetylcholine, dopamine
Abstract: Frontal dementia gives rise to characteristic behavioral changes, which include altered emotions, profound alterations in personality and social conduct, and behavioral alterations constitute core and supportive symptoms laid out in the diagnostic criteria. There are some behavioral symptoms which are considered specific for frontal dementia, being present in at least 50% of cases. These includes loss of basic emotions and social embarrassment, selfishness, disinhibition, irritability, neglect, apathy, altered preference for sweet foods, with a tendency to continue eating for as long as food is present, or to steal food from others plates, motor and verbal stereotypies, wandering, and an absence of insightfulness. Albeit anatomical pathways are well known, there is no known therapy to prevent the advance of frontal dementia. The circuits involve a number of transmitters, receptor subtypes, and second messengers that can be potentially mediated pharmacologically. Though, rational treatments are currently limited . We present the possible actual and future therapeutic choices on the basis of anatomical and biochemical substrates.
Export Options
About this article
Cite this article as:
Moretti Rita, Torre Paola, Antonello M. Rodolfo, Cattaruzza Tatiana and Cazzato Giuseppe, Difficulties in the Management of Frontal Dementia: Therapeutics Strategies, Letters in Drug Design & Discovery 2005; 2 (3) . https://dx.doi.org/10.2174/1570180053765147
DOI https://dx.doi.org/10.2174/1570180053765147 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Central Nervous System Involvement in Pediatric Rheumatic Diseases: Current Concepts in Treatment
Current Pharmaceutical Design Insights into the Structure, Function, and Regulation of Human Cytochrome P450 1A2
Current Drug Metabolism Quantitative Molecular Imaging of Neuronal Nicotinic Acetylcholine Receptors in the Human Brain with A-85380 Radiotracers
Current Medical Imaging Molecular Interaction of Acetylcholinesterase with Carnosic Acid Derivatives: A Neuroinformatics Study
CNS & Neurological Disorders - Drug Targets Hybrid SPECT/CT Imaging in Neurology
Current Radiopharmaceuticals Mitochondrial Aconitase in Neurodegenerative Disorders: Role of a Metabolism- related Molecule in Neurodegeneration
Current Drug Targets Advancements in Treatment Options of Women Infertility
Current Women`s Health Reviews Hyperglycemia, Hypoglycemia and Dementia: Role of Mitochondria and Uncoupling Proteins
Current Molecular Medicine Current Updates in Transdermal Therapeutic Systems and Their Role in Neurological Disorders
Current Protein & Peptide Science Amyloid-β Peptides, Alzheimer's Disease and the Blood-brain Barrier
Current Alzheimer Research Development and Evaluation of a Tactile Cognitive Function Test Device for Alzheimer’s Disease Early Detection
Neuroscience and Biomedical Engineering (Discontinued) Prevalence and associated factors of sarcopenia in elderly subjects with amnestic mild cognitive impairment or Alzheimer disease.
Current Alzheimer Research Immunological Therapeutic and Imaging Approaches for Prion Disease
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Propofol: Therapeutic Indications and Side-Effects
Current Pharmaceutical Design Vasculogenic and Angiogenic Pathways in Moyamoya Disease
Current Medicinal Chemistry Assessment and Treatment of Older People with Depression in a Secondary Mental Health Trust
Current Drug Therapy Proinflammatory Cytokines and Sickness Behavior in Rheumatic Diseases
Current Pharmaceutical Design Haptoglobin Phenotype May Alter Endothelial Progenitor Cell Cluster Formation in Cerebral Small Vessel Disease
Current Neurovascular Research Modulation of Amyloid β Peptide1-42 Cytotoxicity and Aggregation in Vitro by Glucose and Chondroitin Sulfate
Current Alzheimer Research Ring Finger Ubiquitin Protein Ligases and Their Implication to the Pathogenesis of Human Diseases
Current Pharmaceutical Design